Peptides for Skin: GHK-Cu, Collagen Peptides, and What Actually Works

GHK-Cu (Copper Peptide): The Best-Studied Topical Peptide

GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) is a naturally occurring human plasma tripeptide that declines significantly with age. It was first isolated by Dr. Loren Pickart in the 1970s and has since accumulated one of the most substantial evidence bases of any cosmetic peptide.

Mechanisms of GHK-Cu relevant to skin:

• Collagen and elastin synthesis: GHK-Cu upregulates TGF-β and PDGF signaling, stimulating dermal fibroblasts to produce collagen I, III, and elastin. Multiple in vitro studies confirm 2–3x increases in collagen synthesis.
• Matrix metalloproteinase modulation: Simultaneously inhibits collagen-degrading MMPs while stimulating collagen production — a dual effect that maintains structural integrity.
• Antioxidant activity: Copper in the GHK complex participates in superoxide dismutase activity, reducing oxidative stress that accelerates skin aging.
• Wound healing: Applied topically, GHK-Cu accelerates wound healing, reduces scarring, and improves skin barrier function. This is its best-documented clinical application.

Concentrations: effective concentrations in studies range from 0.1% to 1%. Most commercial products containing GHK-Cu use concentrations that may be below effective thresholds. Look for products listing GHK-Cu concentration explicitly.

Other Evidence-Based Topical Peptides

Injectable Peptides for Skin: BPC-157 and Systemic Effects

Some peptide users report significant skin improvements from injectable BPC-157 — particularly faster wound healing, reduced scarring, and improved skin quality. These effects are plausible given BPC-157's mechanisms (angiogenesis, growth factor upregulation, collagen synthesis in tendons is well-documented) and extend to dermal tissue.

The data is primarily preclinical (rat and cell studies show impressive skin and wound healing results). Human anecdotal reports in the peptide community are consistently positive for skin improvements — but controlled human trials specifically for skin outcomes don't exist.

Tesamorelin and other GH secretagogues increase IGF-1, which has documented effects on skin collagen. Some patients on GH peptide therapy report improved skin texture and thickness as a secondary benefit — consistent with the known GH/IGF-1 effect on dermal collagen.

Oral Collagen Peptides: What the RCTs Show

Oral collagen hydrolysates (collagen peptides) have accumulated the most rigorous human trial evidence of any "skin peptide" category:

• A 2014 double-blind, placebo-controlled trial (Skin Pharmacology and Physiology) showed that 2.5g/day of collagen hydrolysate for 8 weeks improved skin elasticity significantly vs. placebo in women aged 35–55.
• A 2019 systematic review of 11 RCTs found consistent improvements in skin hydration, elasticity, and wrinkle reduction with collagen peptide supplementation.
• Dosing: Most studies use 2.5–10g/day. Benefits appear dose-dependent, with 10g/day showing stronger effects in some trials.

Mechanism: Specific collagen dipeptides (Pro-Hyp, Hyp-Gly) are absorbed intact and accumulate in skin. They stimulate fibroblast collagen synthesis — acting more like signaling molecules than protein building blocks.